Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.
Kateryna Fedorov, MD
Advertisement
Articles by Kateryna Fedorov, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Bioequivalent Olaparib Across Previously Approved Cancer Indications
2
Longer-Term Data Help Shape TKI Selection in ROS1+ and ALK+ NSCLC
3
Experts Revisit the Most Notable Data in GU Oncology From ASCO 2026
4
Dr Mardones on Giredestrant Plus Palbociclib in Estrogen Receptor+ Breast Cancer
5